联合用药栓塞硬化治疗静脉畸形的进展

Advances in Combination Therapy of Sclerotherapy on Venous Malformation

静脉畸形的主流治疗方法为血管内栓塞硬化治疗。单一硬化剂的应用受到作用机制或理化性质的限制,不同程度地存在作用较弱或风险较高的局限,难以单独满足表现多样的静脉畸形的治疗要求。因此,为了进一步增强疗效,降低风险,联合用药成为一直以来的研究热点。联合用药方案包括“硬化剂+硬化剂”和“硬化剂+非硬化剂”两种方式。两种硬化剂联合应用可实现优势互补,减量增效,降低风险;而非硬化剂与硬化剂的联用可改善硬化剂的物理性质,增强疗效。因此,在应用单一硬化剂没有取得突破性进展之时,联合用药有可能获得更佳的疗效-风险平衡,因此也是目前研究的主要方向之一。

The mainstream treatment for venous malformation is intravascular sclerotherapy.The limitation of the mechanism of action,or physical and chemical properties of a single sclerosing agent,leading to the existence of limitation of different degrees of weaker effects or higher risks,it is difficult to meet the treatment requirements of various venous malformations.Therefore,in order to further enhance the curative effect and reduce the risk,the combination therapy has become a hot research topic.The combination therapy includes two plans:"sclerosant+sclerosant"and"sclerosant+non-sclerosant".The combination of two sclerosants can achieve complementary advantages,reduce the amount and risks,and increase efficacy;while the combination of sclerosant and non-sclerosant can improve the physical properties of sclerosant and enhance the efficacy.Therefore,when there is no breakthrough progress in a single sclerosant,combination therapy may obtain a better efficacy-risk balance,which will still remain main directions of research.